Not Your Mother’s Menopause

Our mothers had menopause. Many simply did not have a language for it.

They had sleepless nights, sudden heat, heavier or erratic periods, painful sex, aching joints, anxiety that seemed to arrive from nowhere, or a mind that no longer felt as reliable as it once had. Some were told it was ageing. Some were told it was stress. Some were handed a prescription for one symptom while the larger pattern went unnamed. Many said nothing at all.

The silence was so complete that a woman could be struggling beside her sister, her colleague and her closest friend—and each could believe she was the only one.

That is changing. Women are talking publicly about perimenopause and menopause with a frankness that would have been unthinkable a generation ago. The most powerful words in these conversations may be the simplest:

Not only me?

Recognition can be life-changing. It can also be the beginning of better care. But openness alone is not enough. If we are going to replace an old silence, we need to replace it with accurate language, sound evidence and the confidence to ask better questions—not a new marketplace of miracle cures.

The silence had consequences

Menopause was often reduced to a joke about hot flashes or treated as a private matter to be endured. That narrow picture left women unprepared for the breadth of symptoms that can accompany the menopausal transition.

In a 2022 national survey commissioned by the Menopause Foundation of Canada, 46% of women aged 40 to 60 said they felt unprepared for menopause, 54% believed the subject remained taboo, and four in ten felt alone in their experience. Ninety-five per cent reported at least one symptom.

Those numbers describe more than a communication problem. When women do not know that cycle changes, sleep disruption, mood changes, urinary symptoms, vaginal discomfort, cognitive complaints and vasomotor symptoms can occur during the same transition, they may not recognize a pattern worth discussing. They may blame themselves. They may spend years pursuing separate explanations for symptoms that deserve to be considered together.

None of this means that every symptom in midlife is menopause. Palpitations, bleeding changes, depression, fatigue and cognitive changes can have other causes and sometimes need prompt assessment. The point is not to diagnose ourselves. The point is that menopause belongs in the clinical conversation—not outside it.

When the system treated the pieces, not the pattern

Many medical professionals care deeply about their patients. A system can still fail women even when the people inside it are well intentioned.

Primary care appointments are short. Symptoms cross medical specialties. Menopause education has been inconsistent. A woman may see one clinician about sleep, another about heavy bleeding, another about urinary infections and another about anxiety. Each concern may be assessed appropriately on its own, while no one steps back to ask whether hormonal change is part of the larger picture.

The Canadian survey found that fewer than one in four respondents said their family physician had proactively discussed menopause with them. Among the 41% who sought medical advice, 72% described the advice as unhelpful or only somewhat helpful, and four in ten felt undertreated.

These are self-reported experiences rather than a measure of every clinical encounter in Canada. They nevertheless expose a serious gap between the care women need and the care many believe they received.

The harm is not only untreated hot flashes. Poor sleep can affect work and relationships. Genitourinary symptoms can be painful and recurrent. Heavy or irregular bleeding can be disruptive and may require investigation. Feeling unlike oneself without understanding why can produce fear, shame and isolation.

Women were not “too sensitive.” Too often, the map was incomplete.

Research was not built equally around women

The knowledge gap did not appear by accident.

In 1977, the United States Food and Drug Administration recommended excluding women of childbearing potential from early phases of many drug trials. The policy was intended to protect potential pregnancies, but its reach was broad—even women using contraception, women whose partners had vasectomies and single women could be excluded. According to the U.S. National Institutes of Health, the result was a shortage of evidence about how drugs affected women.

Policy changed slowly. In 1993, the NIH Revitalization Act made the inclusion of women and racial and ethnic minority groups in NIH-funded clinical research a matter of law. The Women’s Health Initiative, launched in 1991, was a landmark effort involving more than 150,000 postmenopausal women.

That progress matters. So does the legacy of the earlier exclusion. Research questions, diagnostic norms and medical education developed for decades without women being represented consistently. Conditions that primarily or differently affect women received less attention, and the years after reproduction were too easily treated as a decline to be managed rather than a major life stage worthy of rigorous study.

The Women’s Health Initiative—and the shockwave that followed

No honest account of modern menopause care can ignore the Women’s Health Initiative, commonly called the WHI.

In 2002, one WHI randomized trial of oral conjugated equine estrogen combined with medroxyprogesterone acetate was stopped early after an average follow-up of 5.2 years. For the trial’s purpose—using that regimen to prevent chronic disease—the overall balance of measured risks and benefits was unfavourable. The findings were important.

The public message that followed was much broader: hormone therapy is dangerous.

That was not an adequate translation of the evidence. The average participant was approximately 63 years old, many years beyond the usual onset of menopause, and the trial studied a particular oral regimen for chronic-disease prevention. It did not answer every question about every formulation, dose, route, indication or woman.

Later analyses and current guidance introduced necessary nuance. For many healthy women younger than 60 or within ten years of menopause onset who have bothersome symptoms, the benefit-risk balance of appropriately selected menopausal hormone therapy may be favourable. Risk still varies with personal health history, age, timing, formulation, dose and route. Treatment requires an individualized discussion; it is neither a universal danger nor a universal solution.

The lasting failure was not that researchers reported risk. It was that a complex finding became a blunt warning. Many women and clinicians became fearful, confidence in treatment fell, and the details needed for shared decision-making were lost in the noise.

Social media broke the silence—and opened a new problem

Social media has done something medical leaflets and whispered conversations often did not: it allowed women to describe the whole experience in their own language.

A woman talks about waking at 3 a.m. every night. Another describes a sudden loss of confidence at work. Someone names vaginal dryness, rage, joint pain or the feeling that her brain has become unreliable. Hundreds of others respond: Not only me.

That recognition is not trivial. A peer-reviewed analysis of menopause-related Instagram posts found that lived experiences and support needs appearing prominently on social media were less visible in biomedical literature. Women were not merely repeating medical information; they were identifying what research and clinical conversations had failed to capture.

Online communities can reduce isolation, supply useful vocabulary and prompt a person to seek care. They can also transmit outdated advice, confident misinformation and advertising disguised as education. A 2025 survey of online menopause information-seeking found that social media was the second most-used online resource, while emphasizing the difficulty of judging information quality. Nearly one quarter of respondents used the internet without consulting another source.

A personal story can tell us what happened to one person. It cannot tell us what will be safe or effective for everyone.

The answer is not to retreat into silence. It is to become more discerning:

• Treat lived experience as a clue, not proof.
• Look for the original guideline, study or regulator behind a claim.
• Ask who benefits financially from the advice.
• Be wary of certainty, especially promises to “balance hormones,” reverse menopause or cure a long list of unrelated problems.
• Take questions—not instructions—from social media into a healthcare appointment.

Turn disclosure into an inheritance

Our generation has an opportunity our mothers often did not. We can give the women around us a vocabulary before they are in crisis.

Tell our sisters and friends the whole story

We can talk about sleep, bleeding, cognition, mood, sexual health and bladder changes—not only hot flashes. We can compare experiences without assuming that one woman’s treatment should be another’s. We can say, “This happened to me; it may be worth asking about.”

Teach our daughters before they need the information

Menopause education should not begin when a woman is already frightened by unfamiliar symptoms. Our daughters deserve to understand that perimenopause can begin years before the final menstrual period, that experiences vary, and that seeking care is not weakness or overreaction.

They should also learn that menopause does not explain everything. New, severe or persistent symptoms still deserve proper assessment.

Share evidence, not just conclusions

Instead of forwarding a dramatic clip, we can share the guideline or research behind it. We can explain the difference between a personal account, a survey, an observational study and a randomized trial. We do not need scientific training to ask basic questions: Who conducted this? How many people were studied? Does the claim go beyond what the evidence shows?

Make appointments more useful

Tracking symptoms, cycle changes, medications and their impact can help a clinician see the pattern. A written list of priorities can keep the most important questions from being lost in a short appointment. If a concern is dismissed without explanation, it is reasonable to ask what else could account for it, what warning signs to watch for and when reassessment is appropriate.

Refuse the false choice between silence and hype

Women should not have to choose between a system that minimizes their experience and an online marketplace that monetizes it. We can insist on something better: care that listens, evidence that includes women, and information that respects uncertainty.

This is not our mothers’ menopause

Our mothers’ silence was not consent. Often, it reflected a lack of language, public conversation, credible information and acceptable options.

We cannot give them back the years they spent wondering what was happening. We can change what happens next.

We can name perimenopause before a woman believes she is falling apart. We can make room for stories without mistaking them for medical evidence. We can challenge misinformation without returning to shame. We can teach our sisters, friends and daughters that they are not alone—and that they deserve care grounded in both listening and science.

The most important question may begin as “Not only me?”

The answer should be: No. Not only you. And you do not have to navigate this without a map.